ANTIVIRAL RESEARCH

Scope & Guideline

Leading the Charge Against Viral Infections

Introduction

Delve into the academic richness of ANTIVIRAL RESEARCH with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0166-3542
PublisherELSEVIER
Support Open AccessNo
CountryNetherlands
TypeJournal
Converge1959, from 1981 to 2024
AbbreviationANTIVIR RES / Antiviral Res.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS

Aims and Scopes

The journal 'Antiviral Research' focuses on the cutting-edge research and development of antiviral strategies, encompassing a wide range of methodologies and approaches to combat viral infections. Here are the core areas of focus:
  1. Antiviral Drug Development:
    Research dedicated to the identification and characterization of new antiviral agents, including small molecules, monoclonal antibodies, and vaccines, aimed at various viral infections.
  2. Viral Pathogenesis and Immunology:
    Investigation into the mechanisms of viral replication, host interactions, and immune responses to viral infections, providing insights that inform therapeutic strategies.
  3. Vaccine Research and Development:
    Studies focused on the design, efficacy, and safety of vaccines against viral pathogens, including innovative delivery systems and adjuvants.
  4. Genetic and Molecular Virology:
    Research on the genetic and molecular basis of viral pathogenesis, including studies on viral genome structure, replication mechanisms, and resistance to antiviral agents.
  5. Clinical Research and Epidemiology:
    Studies that evaluate the clinical outcomes of antiviral treatments and the epidemiology of viral infections, providing data to guide public health interventions.
  6. Emerging and Re-emerging Viral Infections:
    Research targeting newly identified viruses and variants, emphasizing the importance of surveillance and rapid response to emerging viral threats.
The journal has seen a significant increase in research focusing on several trending and emerging themes, reflecting the evolving landscape of antiviral research and the urgency brought by recent viral outbreaks:
  1. COVID-19 and SARS-CoV-2 Research:
    A surge in studies related to SARS-CoV-2, including vaccine development, therapeutic interventions, and understanding viral mutations, has become a dominant theme following the pandemic.
  2. Host-Directed Therapies:
    Research on targeting host factors to inhibit viral replication is emerging as a promising strategy, showcasing the potential of host-directed antiviral therapies.
  3. mRNA Technology in Antiviral Vaccines:
    The success of mRNA vaccines against COVID-19 has sparked interest in using mRNA technology for other viral infections, leading to innovative vaccine designs.
  4. Broad-Spectrum Antivirals:
    Increased focus on developing agents that can target multiple viruses or viral families, driven by the need for preparedness against future pandemics.
  5. Nanotechnology in Antiviral Applications:
    Emerging use of nanotechnology for drug delivery systems and vaccine platforms is gaining traction, enhancing the efficacy and reach of antiviral therapies.
  6. Artificial Intelligence in Drug Discovery:
    The application of AI and machine learning in identifying potential antiviral agents and understanding viral-host interactions is becoming increasingly prevalent.

Declining or Waning

While 'Antiviral Research' continues to thrive in many areas, certain themes have seen a decline in focus over recent years. These waning scopes may indicate shifts in research priorities or advancements that have reduced the perceived need for further exploration in these areas:
  1. Traditional Antiviral Agents:
    Research on older antiviral drugs has diminished, as the field shifts focus towards novel therapeutics and combination therapies that address resistance issues.
  2. Non-specific Immunomodulators:
    Interest in broad-spectrum non-specific immunomodulatory agents appears to be waning, with a greater emphasis placed on targeted therapies and precision medicine approaches.
  3. In vitro Studies with Limited Clinical Relevance:
    There is a noticeable reduction in studies that rely solely on in vitro models without clear translational applications, as the field increasingly values research that bridges laboratory findings with clinical outcomes.
  4. Viral Resistance Mechanisms:
    While still important, the frequency of publications specifically focused on mechanisms of resistance in established antiviral therapies has decreased, potentially reflecting advancements in understanding and addressing these issues.

Similar Journals

Hepatitis Monthly

Unveiling breakthroughs in hepatitis management.
Publisher: BRIEFLANDISSN: 1735-143XFrequency: 12 issues/year

Hepatitis Monthly, published by BRIEFLAND in the Netherlands, is a pivotal journal in the fields of hepatology and infectious diseases. Established in 2007, it continues to make significant contributions to the understanding and management of hepatitis and related viral infections with a publication timeline extending through to 2024. Aiming to disseminate high-quality research, the journal serves as a forum for groundbreaking studies and innovations essential for healthcare professionals, researchers, and students alike. While it currently holds Q4 rankings in both hepatology and infectious disease categories, its ongoing commitment to addressing pressing health issues makes it an important resource in the academic community. Although it operates under a traditional access model, Hepatitis Monthly not only publishes original research articles, reviews, and case studies but also encourages the exchange of knowledge that helps shape future research directions and clinical practices. As it continues to explore the complexities surrounding viral hepatitis, this journal invites researchers to contribute to its mission of advancing scientific understanding and improving patient care.

ACTA VIROLOGICA

Fostering collaboration in the fight against viral diseases.
Publisher: FRONTIERS MEDIA SAISSN: 0001-723XFrequency: 4 issues/year

ACTA VIROLOGICA, a key journal in the field of virology and infectious diseases, is published by FRONTIERS MEDIA SA in Slovakia, serving the global scientific community with groundbreaking research since its inception in 1957. This esteemed journal, identified by ISSN 0001-723X and E-ISSN 1336-2305, provides a platform for rigorous peer-reviewed articles that contribute significantly to our understanding of viral pathogens and their implications in medicine. Positioned within the Q3 category for both Infectious Diseases and Miscellaneous Medicine, and a Q4 category for Virology in 2023, ACTA VIROLOGICA offers crucial insights into the evolving landscape of virology research. With its robust accessibility options, this journal appeals to a diverse readership, including researchers, healthcare professionals, and students, fostering a collaborative environment to advance the field of virology. The editorial objective is to enhance the catalog of knowledge pertaining to viruses, promoting innovative approaches in prevention, diagnostics, and treatment. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE CH-1015, SWITZERLAND, ACTA VIROLOGICA continues to be a vital resource in the collective efforts to combat viral disease challenges.

JOURNAL OF MEDICAL VIROLOGY

Transforming Knowledge: Where Virology Meets Innovation.
Publisher: WILEYISSN: 0146-6615Frequency: 12 issues/year

JOURNAL OF MEDICAL VIROLOGY is a prestigious academic publication dedicated to advancing the field of virology and infectious diseases. Published by WILEY, this journal has established itself as a cornerstone within the scientific community since its inception in 1977, and it will continue to provide cutting-edge research until 2024. With an impressive impact factor that places it in the Q1 quartile for both Infectious Diseases and Virology, the journal ranks 14 out of 344 in Medicine - Infectious Diseases and 6 out of 80 in Immunology and Microbiology - Virology according to Scopus metrics. Its focus encompasses a broad spectrum of topics, including viral pathogenesis, diagnostics, treatment strategies, and epidemiology, making it an essential resource for researchers, clinicians, and students alike. Although not an open-access journal, it provides valuable insights and accessible content for subscribers and libraries. The ongoing commitment to high-quality peer-reviewed articles makes JOURNAL OF MEDICAL VIROLOGY a vital platform for disseminating knowledge and fostering innovation in virology and related fields.

Journal of Virology

Advancing Knowledge in Virus-Host Interactions
Publisher: AMER SOC MICROBIOLOGYISSN: 0022-538XFrequency: 12 issues/year

Journal of Virology is a premier scholarly journal dedicated to advancing the field of virology, focusing on the molecular mechanisms of virus-host interactions, viral pathogenesis, and the latest therapeutic and vaccine developments. Published by the American Society for Microbiology, this esteemed journal has been a cornerstone for researchers since its inception in 1967, providing a platform for high-quality, peer-reviewed research. With a commendable impact factor indicative of its relevance and influence, the journal is categorized in the top quartile (Q1) for Virology, Microbiology, and Insect Science, reflecting its significance in these fields. Researchers can access a wealth of studies and findings that shape our understanding of viruses and their interactions with hosts, highlighting its role in both basic and applied sciences. Positioned in the United States, the Journal of Virology serves a global audience, ensuring that cutting-edge discoveries reach professionals, students, and academics alike. Join the conversation as we explore the complexities of virology and its implications for human health and disease.

INTERVIROLOGY

Exploring the frontiers of infectious disease science.
Publisher: KARGERISSN: 0300-5526Frequency: 6 issues/year

INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.

JOURNAL OF GENERAL VIROLOGY

Shaping virology's future with impactful findings.
Publisher: MICROBIOLOGY SOCISSN: 0022-1317Frequency: 12 issues/year

The JOURNAL OF GENERAL VIROLOGY, published by the Microbiology Society, is a premier academic journal dedicated to advancing the field of virology. Established in 1967, this influential journal covers a wide spectrum of research from basic virology to applied studies, serving as a vital resource for researchers, professionals, and students alike. With its ISSN 0022-1317 and E-ISSN 1465-2099, the journal is recognized for its rigorous peer-review process and high-quality publications, attaining a commendable Q2 ranking in the Virology category for 2023. The journal's focus on disseminating innovative findings and fostering critical discussions contributes significantly to the understanding of viral mechanisms, disease processes, and potential therapeutic strategies. Although it does not currently offer Open Access options, the journal remains accessible to the academic community, with a strong commitment to supporting virology research globally. As part of Scopus' top-tier rankings, illustrating its impact within the category of Immunology and Microbiology, the JOURNAL OF GENERAL VIROLOGY continues to play a pivotal role in shaping the future of virological science.

Viruses-Basel

Leading the Charge in Virology Innovation
Publisher: MDPIISSN: Frequency: 12 issues/year

Viruses-Basel, published by MDPI, is a leading interdisciplinary journal focused on the field of virology and infectious diseases, offering a platform for the rapid dissemination of high-quality research. Established in 2009, this open access journal has become an essential resource for researchers and health professionals, ensuring that critical findings are readily available to a global audience. With an impressive Q1 ranking in Infectious Diseases and a Q2 ranking in Virology as of 2023, the journal reflects its commitment to impactful research, validated by its notable positions within Scopus categories—ranked #84 out of 344 in Medicine: Infectious Diseases and #27 out of 80 in Immunology and Microbiology: Virology. The journal adheres to high standards of academic rigor, and by embracing an open access model, it promotes unrestricted access to scientific knowledge, fostering collaboration among researchers, professionals, and students alike. Situated in Basel, Switzerland, the journal serves as a cornerstone in the dissemination of research findings related to viral diseases and their implications on public health.

VIRAL IMMUNOLOGY

Advancing knowledge at the intersection of virus and immunity.
Publisher: MARY ANN LIEBERT, INCISSN: 0882-8245Frequency: 10 issues/year

Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

ANTIVIRAL THERAPY

Transforming the landscape of antiviral pharmacology.
Publisher: SAGE PUBLICATIONS LTDISSN: 1359-6535Frequency: 8 issues/year

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

VIROLOGICA SINICA

Connecting Researchers to the Latest in Virology
Publisher: KEAI PUBLISHING LTDISSN: 1674-0769Frequency: 6 issues/year

VIROLOGICA SINICA, published by KEAI PUBLISHING LTD, is a leading international journal dedicated to the field of virology. With an ISSN of 1674-0769 and E-ISSN of 1995-820X, this esteemed journal showcases cutting-edge research from 2006 to 2024, focusing on critical developments in Immunology, Infectious Diseases, Molecular Medicine, and Virology. As evidenced by its respectable positioning in the Q2 quartile of relevant categories and impressive Scopus rankings—such as Rank #20/80 in Virology—VIROLOGICA SINICA serves as an essential resource for researchers, professionals, and students aiming to deepen their understanding of viral pathogens and their impact on human health. While the journal does not currently offer open access, it remains an invaluable publication for those seeking to stay at the forefront of virology research. Its address is located at 16 Donghuangchenggen North St, Beijing, China, where it continues to foster academic excellence in the rapidly evolving landscape of virology.